FOGHORN THERAPEUTICS INC. - COMMON STOCK

Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor

08 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024

08 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Announces CFO Departure

03 يناير 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting

01 ديسمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

02 نوفمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs

24 أكتوبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress

13 أكتوبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

04 أكتوبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

05 سبتمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML

31 أغسطس 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Chief Medical Officer Succession

08 أغسطس 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update

04 أغسطس 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma

28 يونيو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

07 يونيو 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients

05 يونيو 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update

08 مايو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference

25 أبريل 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics Provides an Update on FHD-609

24 أبريل 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual Meeting

10 أبريل 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting

06 أبريل 2023 16:05:00 بحسب Nasdaq GlobeNewswire